NCT03374943View on ClinicalTrials.gov

A Trial of KB004 in Patients With Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 5, 2017

Primary Completion Date

January 25, 2021

Study Completion Date

September 22, 2021

Conditions
Glioblastoma
Interventions
DRUG

KB004

KB004 is a recombinant, non-fucosylated, IgG1κ (human f-allotype) monoclonal antibody targeting the extracellular ligand binding domain of the EphA3 (ephrin receptor) tyrosine kinase

Trial Locations (2)

3078

Austin Health, Heidelberg

4029

Royal Brisbane and Women's Hospital, Brisbane

Sponsors

Collaborators (1)

Humanigen, Inc.
All Listed Sponsors
collaborator

Humanigen, Inc.

INDUSTRY

lead

Olivia Newton-John Cancer Research Institute

OTHER